Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Equity Average: 2011-2025

Historic Equity Average for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Sep 2025 value amounting to $35.2 million.

  • Lineage Cell Therapeutics' Equity Average fell 46.51% to $35.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year decrease of 46.51%. This contributed to the annual value of $70.9 million for FY2024, which is 3.69% up from last year.
  • Lineage Cell Therapeutics' Equity Average amounted to $35.2 million in Q3 2025, which was down 44.73% from $63.7 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Equity Average high stood at $122.7 million for Q3 2021, and its period low was $35.2 million during Q3 2025.
  • Over the past 3 years, Lineage Cell Therapeutics' median Equity Average value was $68.9 million (recorded in 2024), while the average stood at $66.0 million.
  • In the last 5 years, Lineage Cell Therapeutics' Equity Average grew by 28.69% in 2021 and then crashed by 46.51% in 2025.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Equity Average stood at $106.5 million in 2021, then fell by 29.14% to $75.4 million in 2022, then dropped by 13.79% to $65.0 million in 2023, then rose by 10.07% to $71.6 million in 2024, then tumbled by 46.51% to $35.2 million in 2025.
  • Its Equity Average stands at $35.2 million for Q3 2025, versus $63.7 million for Q2 2025 and $78.7 million for Q1 2025.